Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Increase or decrease of HDL-cholesterol concentrations during pravastatin treatment depending on the pre-treatment

Y Narita1, Y Kitazoe, Y Kurihara

  • 1Center of Medical Information Science, Kochi Medical School, Japan.

European Journal of Clinical Pharmacology
|January 1, 1997
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bronchus-associated lymphoid tissue (BALT) lymphoma and autoimmune disease.

QJM : monthly journal of the Association of Physicians·2022
Same author

FOXO3 is essential for CD44 expression in pancreatic cancer cells.

Oncogene·2016
Same author

Successful treatment of nonunion with teriparatide after failed ankle arthrodesis for Charcot arthropathy.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2013
Same author

TAP-deficient human iPS cell-derived myeloid cell lines as unlimited cell source for dendritic cell-like antigen-presenting cells.

Gene therapy·2012
Same author

Cognitive and affective impairments of a novel SCA/MND crossroad mutation Asidan.

European journal of neurology·2012
Same author

Evaluation of a mirror-polishing technique for fluorocarbon polymer surfaces for reduction of contamination from containers used in ultratrace analysis.

Analytical chemistry·2011

Pravastatin effectively reduced total cholesterol and LDL, but HDL response varied. The drug increased HDL in patients with lower baseline levels, offering personalized cholesterol management insights.

Area of Science:

  • Cardiovascular Pharmacology
  • Clinical Pharmacy
  • Health Informatics

Background:

  • Hospital Information Systems (HIS) provide valuable data for retrospective clinical studies.
  • Statins, like pravastatin, are widely used for cholesterol management.
  • Understanding individual patient responses to statins is crucial for optimizing therapy.

Purpose of the Study:

  • To evaluate the efficacy of pravastatin in a real-world clinical setting using HIS data.
  • To analyze the impact of pravastatin on lipid profiles, including total cholesterol (TC), LDL, HDL, and triglycerides (TG).
  • To investigate factors influencing pravastatin's effect on high-density lipoprotein (HDL) levels.

Main Methods:

  • Retrospective analysis of 130 patients treated with pravastatin (10 mg/day) for at least 4 weeks.

Related Experiment Videos

  • Utilized data from a hospital information system (HIS).
  • Employed t-tests and regression analysis to assess lipid level changes and pretreatment value dependence.

    • Main Results:

    • Pravastatin significantly reduced TC by 18% and LDL by 27%.
    • HDL levels did not show a significant overall change, contrary to some previous reports.
    • Regression analysis revealed that pravastatin increased HDL in patients with baseline HDL < 58 mg/dL and decreased it in those with higher baseline levels.
    • Reductions in TC, LDL, and TG correlated positively with their respective pretreatment values.

    Conclusions:

    • Pravastatin demonstrates significant efficacy in lowering TC and LDL in a clinical setting.
    • The effect of pravastatin on HDL is dependent on the patient's baseline HDL level.
    • HIS data can effectively be used to evaluate drug efficacy and uncover nuanced patient responses.